VTP-43742 (VTP43742) is a highly potent, selective, oral RORγt inverse agonist for the treatment of autoimmune disorders, including multiple sclerosis and psoriasis..

VS-II-173 is a highly potent Pim1 and Pim3 inhibitor with IC50 of 70 and 20 nM respectively, and a potent and selective inducer of AML cell death (IC50=5.5 uM, Molm-13 cell).

VP-14637 (MDT-637) is a novel RSV fusion inhibitor with EC50 of 1.4 nM, reduces RSV replication by inhibition of the F-protein function.

VNRX-5133 is a highly potent and specific beta-lactamase inhibitor, for use in combination with a licensed beta-lactam antibiotic.

VLX1570 is a competitive inhibitor of proteasome DUB activity, with an IC50 of ~10 μM in vitro.

VK4-116 is a novel potent, highly selective dopamine D3 receptor (D3R) antagonist with Ki of 6.8 nM, displays >1,000-fold selectivity over D2R.

VK-1850 (VK1850) is a small-molecule inhibitor of the DNA binding activity of EBNA1 (Epstein-Barr nuclear antigen1).

VK-1727 (VK1727) is a small-molecule inhibitor of the DNA binding activity of EBNA1 (Epstein-Barr nuclear antigen1).

Vitamin B12 is a water-soluble vitamin with roles in brain and nervous system functioning and blood formation through regulation of DNA synthesis, cellular metabolism, fatty acid metabolism, and amino acid metabolism.

VIS351 (VIS-351) is a potent activator of the immunoreceptor tyrosine-based inhibitory motif (ITIM)-mediated function of the IDO1 enzyme with Kd of 1.9 uM.

VinSpinIn is a potent, cell active chemical probe for the Spin family protein with Kd of 10-130 nM for across the family, displays >300-fold selectivity over a panel of methyltransferases.

Vinpocetine (Ethyl apovincaminate) is a synthetic derivative of the vinca alkaloid vincamine, selectively inhibits PDE1 in isolated rabbit aorta with IC50 of 21 uM.

Vilazodone is an inhibitor of ST (serotonin transporter and uptake) (IC50 = 0.5 nM) and SR-1A activator (partial agonist) (IC50 = 0.2 nM; IA = ~60-70%).

Vilazodone (EMD 68843) is a combined serotonin specific reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist currently under clinical evaluation.

Vilaprisan (BAY 1002670) is a highly potent and selective progesterone receptor (PR) modulator.

Vigabatrin Hcl(γ-Vinyl-GABA; Sabril) is a structural analog of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) that irreversibly inhibits the catabolism of GABA by GABA transaminase.

VHL-IN-15 is a potent (IC50=4.1 uM) von Hippel–Lindau protein (VHL) ligand that disrupts the VHL/HIF-1α interaction..

VHL-alkyne is a VHL ligand for PROTAC synthesis..

VGTI-A3-03 is a novel potent, highly virus-specific inhibitor of DENV replication with greatest activity against DENV serotype 2 (IC50=25 nM), directly bind DENV capsid protein.

VGSC blocker 1 is a potent, small molecule blocker of neonatal isoform of the VGSC subtype, Nav1.5 (nNav1.5), blocks INa peak currents 34.9% at 1 uM.

Vestipitant (GW597599) is a potent, selective, orally active NK1 receptor antagonist with pKi of 9.65.

Vestipitant (GW597599) is a potent, selective, orally active NK1 receptor antagonist with pKi of 9.65.

VERU-111 analogue 13f is a novel potent colchicine binding site inhibitor (CBSI) in tubulin with potential anticancer activities.

Vernakalant Hcl(RSD-1235) is an investigational mixed ion channel blocker that can terminate acute atrial fibrillation (AF) in humans at 2 to 5 mg/kg and may be more atrial-selective than available agents; in treatment of antiarrhythmic.

Veratramine(NSC17821; NSC23880) is useful as a signal transduction inhibitor for treating tumors.

Verapamil is a CYP3A inhibitor.

VER-50589 is a potent HSP90 inhibitor with IC50 of 21 nM for HSP90β.

Venlafaxine Hydrochloride is a dual ST and SLC6A2 (serotonin and noradrenalin re-uptake) inhibitor that displays ~ 30-fold higher affinity for ST (SERT) (Ki = 82 nm) than SLC6A2 (NET) (Ki = 2480 nM).

Velusetrag (TD-5108) is a potent, selective and oral 5-HT4 receptor agonist with pKi of 7.7, shows >500-fold selectivity over other 5-HT receptors.

Velusetrag (TD-5108) is a potent, selective and oral 5-HT4 receptor agonist with pKi of 7.7, shows >500-fold selectivity over other 5-HT receptors.